November 6, 2024
Consumers who purchased CVS Pharmacy-branded maximum strength lidocaine patches, creams, roll-ons, or spray products in the past few years have three more days to file a claim and get a piece of a $3.8 million settlement.


Consumers who purchased CVS Pharmacy-branded maximum strength lidocaine patches, creams, roll-ons, or spray products in the past few years have three more days to file a claim and get a piece of a $3.8 million settlement.

Some customers alleged that the packaging of the products was deceptive because it led them to believe the product provided “maximum strength” lidocaine. CVS Pharmacy has denied any wrongdoing with regard to the packaging but agreed to a settlement to resolve the matter. The deadline for customers to file a claim in the settlement is Nov. 20.

BIDEN STOKES NEWSOM PRESIDENTIAL BUZZ AT APEC EVENT ALONGSIDE CALIFORNIA GOVERNOR

There are two ways customers can submit claims for the settlement. Eligible customers may submit up to three claims worth $4.50 per unit without proof of purchase, or they may submit a claim with proof of purchase for $4.50 per unit, with no limit on how many claims they make. The claims can be made one of these two ways, but not using both methods.

Customers who purchased the products from Dec. 11, 2017, through July 18, 2023, are eligible for the settlement, but they must submit a claim to receive money.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

The court has scheduled a final approval hearing for the settlement for Dec. 19. The hearing will allow customers to speak about the proposed settlement with the pharmacy over the lidocaine products. More information on the settlement, including how to file a claim, can be found on the court-authorized website.

Among the other class-action settlements with upcoming deadlines is one for Capital One customers affected by a hack in which millions of customers’ personal information was accessed. Affected customers have until Nov. 27 to claim a piece of that settlement with Capital One.

Leave a Reply